Pharmaceutical Product Development, LLC (PPD) has entered into an agreement to acquire Evidera, a provider of evidence-based solutions to demonstrate real-world effectiveness and value of biopharmaceutical products. The acquisition expands PPD’s peri- and post-approval capabilities. The acquisition, subject to certain closing conditions, is expected to close in 3Q16.
 
Evidera will become a wholly owned subsidiary of PPD, providing peri- and post-approval studies, health economics, outcomes research, epidemiology and market access consulting. The acquisition will help clients address the growing demand for evidence from regulators, payers and health technology assessment agencies.
 
“Our acquisition of Evidera demonstrates PPD’s commitment to strategic investments that enable our clients to advance the generation of real-world evidence to more efficiently deliver life-changing therapies that improve health,” said David Simmons, chairman and chief executive officer of PPD. “We are dedicated to providing our clients a superior integration of scientific knowledge, technology and high-quality delivery to maximize the productivity of their R&D investments and to accelerate patient access to life-changing therapies.”
 
Jon Williams, who will continue to lead Evidera, said, “This acquisition brings together two leaders in their respective sectors. PPD’s unparalleled reputation for quality makes them an ideal match for Evidera, and joining the PPD family expands our global footprint and operational capabilities. The combination of Evidera and PPD will provide customers with a seamless and unmatched set of solutions across the product life cycle.”
 
Evidera will continue to operate its office locations in North America and Europe.